HUM-MOLGEN events: HIGH-THROUGHPUT TARGET VALIDATION

HUM-MOLGEN -> Events -> Meetings and Conferences

July 26, 2001

Cambridge Heathtech Institute, Boston, Massachusetts
November 14-15, 2001

Target validation involves taking steps to prove that a DNA, RNA, or protein molecule is directly involved in a disease process and is therefore a suitable target for development of a new therapeutic compound. Sequence homology studies have successfully classified genes into target families such as GPCRs, ion channels, and kinases. The enormous task of deciphering which of these targets that share sequence but not function are key players in disease and which should be used for subsequent drug development needs to be addressed in a cost-effective and efficient manner. Genes that do not belong to an established family are critical to many disease processes and also need to be validated as potential drug targets. This further extends the need for high-throughput approaches to determine which targets should be explored and which should not. The challenge of designing, identifying, and formulating a potential lead is great; it is therefore not only important to validate targets quickly and efficiently at the early stages of development but it is also important to make the right choices to save time, resources, and money in the later stages. Anyone interested in the challenge of making target validation more high throughput, efficient, and effective should attend this conference.

Organized by:

CHI

Invited Speakers:

Dr. Aram Adourian, Beyond Genomics, Inc.
Dr. Douglas A. Bakan, MetaProbe LLC
Dr. Deborah L. Baly, Bayer Corporation
Mr. Andrew Branca, Cambridge Healthtech Institute
Dr. Ronald R. Breaker, Yale University
Dr. Michael R. Briggs, Pharmacia Research & Development
Dr. Daniela Brunner, PsychoGenics, Inc.
Dr. Yen Choo, Gendaq Ltd.
Dr. Nicholas M. Dean, GeneTrove (a Division of Isis Pharmaceuticals)
Ms. Brenda K. Eustace, Tufts University
Dr. Steven A. Farber, Thomas Jefferson University
Dr. Kevin FitzGerald, Bristol-Myers Squibb Company
Dr. Thomas Henkel, MediGene AG
Dr. Marnie L. MacDonald, Odyssey Pharmaceuticals, Inc.
Dr. Bruce Roberts, Genzyme Corporation
Dr. Andreas P. Russ, Ingenium Pharmaceuticals AG
Dr. David E. Szymkowski, Roche Pharmaceuticals

Deadline for Abstracts:

October 19, 2001

Registration:

Available on-site

E-mail:

jlaakso@healthtech.com

Posted by:

Jennifer Laakso

Host:

wks217.healthtech.com